Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cyclooxygenase-1

6

Cyclooxygenase-2

6

Interleukin-8 receptors, CXCR1/CXCR2

6

Cyclooxygenase

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

7

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1986

6

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Osteoarthritis

7

Rheumatoid arthritis

7

Migraine

6

Musculoskeletal pain

6

Pain

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

7

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

6

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Rhône-Poulenc

6

Hoffman-La Roche

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

EVMPD

7

FDA UNII

7

PUBCHEM

7

SMS_ID

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

MUSCULO-SKELETAL SYSTEM

3

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

3

TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

2

ANALGESICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

3

TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

2

OPIOIDS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antiinflammatory preparations, non-steroids for topical use

2

Propionic acid derivatives

2

Opioids in combination with non-opioid analgesics

1

Oxicams

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DEXKETOPROFEN

6KD9E78X68

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

TENOXICAM

Z1R9N0A399

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Postoperative pain

Rheumatoid arthritis

Tenoxicam (Mobiflex), an anti-inflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. The anti-inflammatory effects of tenoxicam may result from the inhibition of the enzyme cyclooxygenase...

and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss. Taking tenoxicam with other drugs can increase the chance of side effects or alter the therapeutic effect of tenoxicam or the other drug, depending on the combination. Drug types the tenoxicam may interact with include: other analgesic NSAIDs, salicylates such as aspirin, antacids, anticoagulants, cardiac glycosides, ciclosporin, quinolone antibiotics, lithium therapy, diuretics and anti-hypertensives, methotrexate, oral anti-diabetics, cholestyramine, dextromethorphan, mifepristone, corticosteroids, anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs), tacrolimus, zidovudine, and gold/penicillamine. Tenoxicam is available as a prescription-only drug in the United Kingdom and other countries, but not in the US. Outside of the United Kingdom, tenoxicam is also marketed under brand names including Tilatil, Tilcitin, and Alganex. Tenoxicam belongs to the class of NSAIDs known as oxicams. It is used to relieve inflammation, swelling, stiffness, and pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis (a type of arthritis involving the spine), tendinitis (inflammation of a tendon), bursitis (inflammation of a bursa, a fluid-filled sac located around joints and near the bones), and peri-arthritis of the shoulders or hips (inflammation of tissues surrounding these joints).

KETOPROFEN ARGININE

029SOQ8920

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

DEXKETOPROFEN TROMETHAMINE

N674F7L21E

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

KETOPROFEN LYSINE

5WD00E3D4C

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (EPIMERIC)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

KETOPROFEN SODIUM

5R10M39KS7

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

KETOPROFEN

90Y4QC304K

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1986

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Cyclooxygenase-2

Cyclooxygenase-1

Interleukin-8 receptors, CXCR1/CXCR2

Conditions:

Rheumatoid arthritis

Primary dysmenorrhea

Pain, postoperative

Musculoskeletal pain

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blockin...

g the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1